DALLAS, Jan. 25, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biopharmaceutical company Hana Biosciences Incorporated (OTCBB:HNAB). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/HNAB
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Hana Biosciences Incorporated (HNAB) engages in the biotechnological development and commercialization of cancer therapies to enhance efficacy to current standard-of-care protocols for the treatment of various cancers. The Company presently has four drug candidates under development, including Marqibi ®, Menadione Topical Lotion, Brakiva (TM) and Alocrest (TM).
In the report, the analyst notes:
"As of September 30, the Company's drug candidate Marqibo is in phase II for the treatment of metastatic uveal melanoma. The Company achieved its target enrollment in 2009, with plans for a confirmatory trial of the drug in 2011 and intentions to file for a New Drug Applications (NDA) with the Food and Drug Administration (FDA) in 2010. Further progression toward commercialization of Marqibo is dependent upon pending results of phase II studies.
"The Company expects to report an additional $5.0 million of expenses related to Marqibo in its coming fourth-quarter earnings report. In its latest 10-Q filing in October, the Company said it needs an additional $8.0 million for an accelerated approval of Marqibo and $45.0 million for full FDA approval. Marqibo is expected to undergo three to four more years of development and FDA approval time before the Company can embark with commercialization of the product."
To read the entire report visit: http://www.beaconequity.com/i/HNAB
See what investors are saying about these stocks at penny stock forum.
BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.